The clinical impact of single inhaler therapy in asthma

Clinical & Experimental Allergy, 05/01/2012

Despite fewer severe exacerbations with SMART therapy as compared to ICS monotherapy or lower dose ICS/LABA therapy, the strategy produces poor day–to–day control of symptoms and is associated with increasing inflammation. The symptom–reactive strategy described as SMART therapy is associated with poor symptom control of asthma.

Print Article Summary Cat 2 CME Report